EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan
Sponsor: Daiichi Sankyo